A total of 303 patients were enrolled, of whom 298 were included in the intention‐to‐treat (ITT) population. Results reported here are from a prespecified interim analysis, for the evaluation of the study's primary endpoint: the percentage of patients with serum 25‐hydroxyvitamin D (25(OH)D) levels above 30 ng/ml after 4 months. This 1‐year, phase III–IV, double‐blind, randomized, controlled, multicenter clinical trial assessed the efficacy and safety of calcifediol 0.266 mg soft capsules in vitamin D–deficient postmenopausal women, compared to cholecalciferol. Few supplementation guidelines mention calcifediol treatment, despite being the direct precursor of calcitriol and the biomarker of vitamin D status. Furthermore, vitamin D deficiency has become a worldwide health issue. Vitamin D has shown to play a role in multiple diseases due to its skeletal and extraskeletal actions.
0 kommentar(er)
